Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Mechanism Study in Systemic Lupus Erythematosus
ChiCTR2300075081Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by Tianjin Medical University General Hospital. Primary endpoint: SLE Responder Index-4 (SRI-4). Started Aug 2023; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2300075081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075081.